vofopitant

02/14/2003 - "However, the latency time to the first emesis was not affected by GR205171. "
01/01/1999 - "To identify this site, the effects of the NK1 receptor antagonist GR205171 on the activities of neurons comprising the central pattern generator (CPG) for vomiting were observed in decerebrate paralyzed dogs. "
08/27/1996 - "The trifluoromethyl compound, GR205171, was the most potent antagonist with regard to the ability to inhibit emesis induced by X-irradiation. "
02/01/1999 - "The stimuli for emesis after PONV are multifactorial and the efficacy of GR205171 in this study supports the broad spectrum potential for NK1 receptor antagonists in the management of postoperative emesis. "
02/14/2003 - "Direct injection of cisplatin (10 microg/kg) into the fourth ventricle produced emesis, which was reduced by GR205171 administered via the peripheral or central route. "

01/15/1997 - "Such a profile of action suggests that GR205171 may have potential as a novel therapeutic agent in the treatment of migraine headache."
09/01/1998 - "In this study, one such candidate compound, GR205171, a highly lipophilic potent neurokinin-1 antagonist, has been tested in a model of trigeminovascular nociception with considerable predictive value for anti-migraine activity. "
01/01/2021 - "However, GR205171, which failed in clinical trial for both abortive and preventive treatment of migraine, had no effect. "
08/01/1998 - "Glaxo Wellcome is developing the NK1 antagonist GR-205171 for the potential treatment of chemotherapy- and radiotherapy-induced emesis, post-operative nausea and emesis, and migraine. "
01/15/1997 - "The in vivo activity of GR205171, a novel, highly potent non-peptide tachykinin NK1 receptor antagonist, has been investigated in the trigeminovascular system in order to assess its potential as an acute therapy for migraine headache. "

02/01/1999 - "GR205171 produced greater control of PONV than placebo over the 24-h assessment period. "
02/01/1999 - "The stimuli for emesis after PONV are multifactorial and the efficacy of GR205171 in this study supports the broad spectrum potential for NK1 receptor antagonists in the management of postoperative emesis. "
02/01/1999 - "In this double-blind, randomized, parallel group study, we have investigated the antiemetic activity of the potent and selective NK1 receptor antagonist GR205171 25 mg i.v. compared with placebo in the treatment of established postoperative nausea and vomiting (PONV) in patients after major gynaecological surgery performed under general anaesthesia. "
02/01/1999 - "Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery."

08/01/1998 - "The greatest inhibition of both nausea-like behaviour and vomiting was observed in piglets receiving multiple injections of GR205171. "
07/01/2000 - "Hence the efficacy of the NK1 antagonist GR205171 in combination with the 5-HT3 antagonist ondansetron (Zofrantrade mark) was assessed in motion-induced nausea. "
08/01/1998 - "Glaxo Wellcome is developing the NK1 antagonist GR-205171 for the potential treatment of chemotherapy- and radiotherapy-induced emesis, post-operative nausea and emesis, and migraine. "
08/01/1998 - "The effects of GR205171, a selective tachykinin NK1 receptor antagonist, were investigated on both the acute and delayed phases of cisplatin-induced nausea-like behaviour and vomiting in the conscious piglet. "
07/01/2000 - "Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man."

03/01/2011 - "An exploratory analysis showed that GR205171 treatment was associated with significant improvement compared to placebo on the CAPS hyperarousal symptom cluster. "